Abstract
The area of biological and targeted therapies exploded in the late 1990s. After obtaining good results in hematological malignancies, cancer treatment is now being based on monoclonal antibodies. ASCO has integrated various areas of biological therapy into its scope of clinical activity. Trastuzumab (Heceptin) and bevacizumab (Avastin), antibodies targeting HER-2 and vascular endothelial growth factor, respectively, were approved by the United States Federal Drug Administration for first-line treatment of metastatic breast and colorectal cancer in combination with chemotherapy. Bevacizumab is the first approved agent to target tumor angiogenesis. This drug is now combined with chemotherapy to treat breast, lung, and colorectal cancer. In the past several years, significant advances in the underlying biological mechanisms of renal cell carcinoma, particularly the role of tumor angiogenesis, have made it possible to design molecularly targeted therapeutics. This meeting review is organized by tumor type and biotherapy modality.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Targeted Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
